Attorney Docket No.: BMED-004/01US

Attorney File No.: 34728/US/2/AMP/GKS/THR (470298-00164)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication of

MORAN

Serial No. 10/004,118

Filed: October 30, 2001

For: M

Method for Short-Term and

Long-Term Drug Dosimetry

Art Unit: 1646

Examiner: Janet L. Andres

EXPRESS MAIL LABEL NO.:

EV 529551710 US

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REVOCATION AND SUBSTITUTION OF POWER OF ATTORNEY

Dear Sir:

The undersigned assignee of the entire interest in the above subject patent application hereby revokes all powers of attorney previously granted in connection with this application and hereby appoints the Dorsey & Whitney LLP attorneys and agents associated with <u>Customer Number 32940</u> to prosecute the patent application identified above and to transact all business in the Patent and Trademark Office connected therewith, including full power of association, substitution, and revocation, and said appointment to be to the exclusion of the inventor(s) and his (their) attorney(s) in accordance with the provisions of 37 C.F.R. 1.32; provided that if any one of said attorneys ceases being affiliated with the law firm of DORSEY & WHITNEY LLP as partner, employee or of counsel, such attorney's appointment as attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Assignee has reviewed the assignment documents and believes title of the above subject patent application resides in the assignee.

U.S. Serial No.: 10/004,118 Filed: October 30, 2001

Please direct all telephone calls to Gurjeev K. Sachdeva at (415) 781-1989.

Please direct all future correspondence to the address associated with <u>Customer Number 32940</u>, currently:

DORSEY & WHITNEY LLP Intellectual Property Department Four Embarcadero Center, Suite 3400 San Francisco, California 94111-4187

Telephone: (415) 781-1989 Facsimile: (415) 398-3249

Date: 18 January, 2005

INTARCIA THERAPEUTICS, INC.

Name: <u>Curtis Scribner, M.D.</u> Chief Regulatory Officer and

Title: Vice President, Regulatory Affairs